BioCentury
ARTICLE | Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

The firm’s evolving strategy to invest earlier in companies’ lifecycles could be affected by COVID-19

March 31, 2020 7:04 AM UTC
Updated on May 2, 2020 at 12:00 AM UTC

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing on its own or creating companies from scratch. But as the firm braces for COVID-19’s ongoing effects, it could seek out later-stage deals for awhile as the outbreak’s influence deal flow and the marketplace become clear.

Managing Partner Pieter van der Meer told BioCentury that while Gilde has historically invested somewhat later in companies’ life cycles and held stakes up to about 20%, the firm is now aiming to own larger minority positions that could exceed 30% via Gilde Healthcare V. The firm invests in therapeutics, digital health and medtech companies, emphasizing those that deliver better outcomes to patients while reducing costs to the healthcare system...

BCIQ Company Profiles

Gilde Healthcare Partners B.V.